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Abstract
BACKGROUND: Various radiometal complexes have been de-
veloped for tumour imaging, especially Ga-68 tracer. In this work,
the development of a radiogallium bis(thiosemicarbazone) com-
plex has been reported.
MATERIAL AND METHODS: [67Ga]acetylacetonate bis(thio-semi-
carbazone) complex ([67Ga]AATS) was prepared starting with
[67Ga]Gallium acetate and freshly prepared acetylacetonate
bis(thiosemicarbazone) (AATS) for 30 min at 90∞C. The partition
co-efficient and stability of the tracer was determined in final
solution (25∞C) and the presence of human serum (37∞C) for up
to 24 hours. The biodistribution of the labelled compound in
wild-type and fibrosarcoma-bearing rodents were determined
for up to 72 hours.
RESULTS: The radiolabelled Ga complex was prepared to
a high radiochemical purity (> 97%, HPLC) followed by ini-
tial biodistribution data with the significant tumour accumu-
lation of the tracer at two hours, which is far higher than free
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Ga-67 cation, while the compound wash-out is significantly
faster.
CONCLUSION: The above-mentioned pharmacokinetic proper-
ties suggest an interesting radiogallium complex prepared by
the PET Ga radioisotope, 68Ga, in accordance with the physical
half life, for use in fibrosarcoma tumours and possibly in other
malignancies.
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Introduction
The physical properties and availability of gallium-67 make it
an interesting nuclide for radiopharmaceutical research [1].
A growing increasing trend in the production and use of PET gal-
lium nuclides in nuclear medicine has offered new opportunities
for researchers to focus on the production of new 67Ga-radio-phar-
maceuticals for feasibility studies for their future PET gallium ho-
mologues.
The auger electrons emitted by 67Ga possess potent cytoto-
xicity pointing towards potential therapeutic applications of the ra-
dionuclide [2], while the positrons emitted by 68Ga may also have
therapeutic applications in the prevention of restenosis by intra-
coronary radiation therapy [3].
Thiosemicarbazone gallium complexes have shown inter-
esting anti-proliferative activity in vitro and in vivo [4]. The most
studied compounds are nitrogen-containing heterocycles [5];
this is possibly due to their resemblance to the pyridoxal me-
tabolites that attach to co-enzyme B6-dependant enzymes and
cause enzyme inhibition [6]. Various gallium-based radiotrac-
ers have been reported by Green et al. [7–9], including an ace-
toacetate gallium-67 complex as a potential radiopharmaceu-
tical [10].
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However, there are rare examples of gallium bis thiosemicar-
bazones, according to our knowledge, while copper analogues of
bis thiosemicarbazones have been extensively studied [11, 12].
Their biological activity and structure-activity have been well re-
ported and the retention mechanisms in hypoxic and normoxic tu-
mours are cited.
Usually, traditional bis thiosemicarbazones such as ATSM,
PTSM, etc. do not form complexes with gallium due to many chem-
ical and molecular orbital considerations. However, in our expe-
riments we were able to detect interesting radiolabelling proper-
ties for acetyl acetoacetate bis thiosemicarbazone homologues.
Such complexes have not been reported by others, while infor-
mation on the copper and nickel complexes have recently been
reported [13].
Recently we have reported the radiosynthesis of 67Ga-labelled
pyridine-based thiosemicarbazone (67Ga-APTSM2) [14] as well as
its evaluation in fibrosarcoma-bearing mice using scarification and
SPECT studies [15].
Due to the interesting anti-neoblastic activity of gallium thiosemi-
carbazones and the possibility of developing a new series of
67Ga-labelled acetyl acetate bis-thiosemicarbazonate complexes
as possible tumour imaging agents using SPECT, the production,
purification, and biodistribution studies of [67Ga]-AAPS were inves-
tigated (Figure 1).
Materials and methods
Enriched zinc-68 chloride with a purity of more than 95% was
obtained from the Ion Beam Separation Group at the Agricultu-
ral, Medical, and Industrial Research School (AMIRS). Production
of 67Ga was performed using the Nuclear Medicine Research
Group (AMIRS) 30 MeV cyclotron (Cyclone-30, IBA). Other che-
micals were purchased from the Aldrich Chemical Co. (Germa-
ny) and the ion-exchange resins from Bio-Rad Laboratories (Ca-
nada). NMR spectra were obtained on a FT-80 Varian instrument
(80MHz) with tetramethylsilane as the internal standard. Infrared
spectrum was measured on a Perkin-Elmer 781 spectrometer
using a KBr disc. Mass spectrum was recorded by a Finnigan
Mat TSQ-70 spectrometer. Thin layer chromatography (TLC) for
cold compounds was performed on polymer-backed silica gel
(F 1500/LS 254, 20 ¥ 20 cm, TLC Ready Foil, Schleicher
& Schuell®, Germany). The normal saline and sodium acetate used
Table 1. Nuclear properties of Ga radionuclides
Properties 67Ga 68Ga 66Ga
Gamma energy (keV) 3      185      300 511(b+) 511(b+)   834   1039 2752
b–/b+ energy 84  92 1900(b+) 4153(b+)
Mode of decay EC to 67Zn 10% EC to 68Zn 43% EC to 66Zn
90%  b+ 57%  b+
Nuclear reaction 68Zn(p,2n)67Ga 68Ge Daughter 66Zn(p,n)66Ga
66Zn(b,2n)68Ge
Natural abundance  (%) (18%) (28%) (28%)
Possible contaminations 66Ga, 65Zn 68Ge 65Zn
Proton energy (MeV) 12–22 12–22 6–15
Figure 1. Synthesis of [67Ga]AATS.
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for labelling were of high purity and had been filtered through
0.22 mm Cativex filters. Instant thin layer chromatography (ITLC)
was performed by counting Whatman No. 2 papers using a thin
layer chromatography scanner, Bioscan AR2000, Bioscan Europe
Ltd. (France). Analytical high-performance liquid chromatogra-
phy (HPLC), used to determine the specific activity, was performed
by a Shimadzu LC-10AT, armed with two detector systems, flow
scintillation analyzer (Packard-150 TR), and UV-visible (Shimad-
zu) using a Whatman Partisphere C-18 column 250 × 4.6 mm,
Whatman, NJ (USA). Biodistribution data were acquired by count-
ing normal saline-washed tissues after weighting on a Canber-
ra‘ high-purity germanium (HPGe) detector (model GC1020-
-7500SL). Radionuclidic purity was checked with the same de-
tector. For activity measurement of the samples, a CRC Capin-
tech Radiometer (NJ, USA) was used. All calculations and ITLC
counts were based on the 184 keV peak. Animal studies were
performed in accordance with the United Kingdom Biological
Council's Guidelines on the Use of Living Animals in Scientific In-
vestigations, 2nd edition.
Production of 67Ga
 68Zn(p,2n)67Ga was used as the best nuclear reaction for the
production of 67Ga. Other impurities could be removed in the ra-
diochemical separation process. After the target bombardment pro-
cess, chemical separation was carried out in no-carrier-added form.
The irradiated target was dissolved in 10 M HCl (15 ml) and the
solution was passed through a cation exchange resin (AG 50W,
H+ form, mesh 200–400, h: 10 cm, Δ: 1.3 cm) which had been
preconditioned by passing 25 ml of 9 M HCl.
The column was then washed with 25 ml of 9M HCl at a rate of
1 ml/min to remove copper and zinc ions. To the eluent, 30 ml of
water plus about 100 ml of a 6 M HCl solution was added. The
latter solution was loaded on another exchange resin (AG1X8 Cl-
form, 100–200 mesh, h: 25 cm, Δ: 1.7 cm) pretreated with 6 M HCl
(100 ml). Finally, the gallium-67 was eluted as [67Ga]GaCl3 using
2 M HCl (50 ml); the whole process took about 60 min.
Quality control of the product
Control of radionuclide purity
Gamma spectroscopy of the final sample was carried out count-
ing in an HPGe detector coupled to a Canberra‘ multi-channel
analyzer for 1000 seconds.
Chemical purity control
The presence of zinc cation was detected by visible colorimet-
ric assays. Even at 1 ppm of standard zinc concentration, the pink-
ish complex is visible to the naked eye, while the test sample re-
mained similar to the blank [16]. The amount of copper cation was
checked in the final solution using colour formation with dithizone
reagent [17].
Production of acetylacetonate
bis(thiosemicarbazone) (AATS) [3]
This compound was prepared with slight modifications to the
reported method [18]. Briefly, to a transparent stirring mixture of
thiosemicarbazide (2 mmol) (2) in 5% acetic acid at 50oC, was add-
ed drop wise freshly distilled acetyl acetone (1 mmol) (1) during 5
minutes. The mixture was stirred for another 30 minutes at 50oC.
The reaction mixture was cooled down in an ice bath and the pre-
cipitate was filtered. The precipitate was washed with water
(10 ml) and ethanol (20 ml) and finally dried in oven at 70–80oC for
at least 8 hours. The residue can be further purified by refluxing the
mixture of the precipitate in 80% acetic acid at 50–70oC for 10––14
hours. The filtered mass was heated in an oven at 80oC and finally
crystallized from hot ethanol to give a light yellow powder (60%)
m.p. 148–150oC. 1H NMR (CDCl3) d (ppm) 9.19 (s, 1H, NH), 7.91
(s, 2H, -CH2-), 2.86 (d, 6H, CH3-C=N). IR (CHCl3) l max 3535, 3129,
2956, 2495, 2361, 1563, 1399, 1215, 1041, 661, 556. Mass (elec-
trospray) 190.1 (M+).
Preparation of [67Ga]acetylacetonate
bis(thiosemicarbazone) complex ([67Ga]AATS):
The acidic solution (2 ml) of [67Ga]GaCl3 (111 MBq, 3 mCi)
was transferred to a 5 ml-borosilicate vial containing 0.5 ml of
acetate buffer pH.5.5. Fifty microlitres of acetylacetonate
bis(thiosemicarbazone) (AATS) in absolute ethanol (1 mg/ml ª
ª 260 nmoles) was added to the gallium-containing vial and
vortexed at 80–90oC for 30 minutes. The mixture was then cooled
to room temperature. The vial mixture was diluted by the addi-
tion of normal saline (4.5 ml). The active solution was checked
for radiochemical purity by ITLC and HPLC. In case of high free
gallium content presence, the mixture (about 5 ml) was cooled
in an ice bath and rapidly injected into a C18 Sep-Pak column
pretreated with 5ml of ethanol and 2 ml of water. The column
was washed with water (4 ml) and purged with a stream of dry N2.
The labelled compound was finally eluted using 0.2 ml-portions
of absolute ethanol, and the fractions were counted in an HPGe
detector. The vial containing the maximum radioactivity was di-
luted to a 5% solution by the addition of normal saline followed
by passing through a 0.22 mm filter, and the pH was adjusted
to 5.5–7.
Quality control of [67Ga]AATS
Radio thin layer chromatography
A 5 ml sample of the final fraction was spotted on a chromato-
graphy Whatman No. 2 paper, and developed in 10% ammonium
acetate:methanol (1:1) mixture as the mobile phase.
High performance liquid chromatography
HPLC was performed with a flow rate of 1 ml/min, pressure:
130 kgF/cm2 for 20 min. Radiolabelled compound was eluted us-
ing a mixture of two solutions (A: acetonitrile + 0.1% TFA/water +
+ 0.1% TFA, 90:10) using reversed phase column Whatman Parti-
sphere C18 4.6 ¥ 250 mm.
Stability of [67Ga]AATS complex in the final product
Stability tests were based on previous studies performed
for radiolabelled metal complexes [19]. A sample of [67Ga]AATS
(5 mCi) was kept at room temperature for 4 days while being
checked by RTLC every half an hour. A micropipette sample
(5 ml) was taken from the shaking mixture, and the ratio of free
radiogallium to [67Ga]AATS was checked by instant thin layer
chromatography.
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Serum stability studies
To 36.1 MBq (976 mCi) of [67Ga]AATS was added 500 ml of
freshly prepared human serum, and the  resulting mixture was in-
cubated at 37°C for 2 days. Aliquots (5-ml) were analyzed by ITLC
after 0, 0.25, 0.5, 1, 2, and 3 hours of incubation to determine the
stability of the complex.
Determination of partition coefficient
The partition coefficient of the [67Ga]AATS was measured fol-
lowing 1 minute of vigorous vortex mixing of 1 ml of 2-octanol and
1 ml of isotonic acetate-buffered saline (pH = 7) with approximately
3.7 MBq (100 mCi) of the radiolabelled copper complex at 37°C.
Following further incubation for 5 minutes, the octanol and aque-
ous phases were sampled and counted in an automatic well
counter. A 500 μl sample of the octanol phase from this partition-
ing was repartitioned two to three times with fresh buffer to ensure
that traces of hydrophilic 67Ga impurities did not alter the calculat-
ed P values.
The reported log P values are the average of the second and
third extractions from three to four independent measurements,
log P values represent the mean (standard deviation) of five mea-
surements.
Induction of fibrosarcoma tumours in rodents
Tumour induction was performed by the use of poly aromatic
hydrocarbon injection in rodents, as reported previously [20].
For tumour model preparation, 10 μl of 3-methyl cholanthrene
solution in extra-virgin olive oil (4 mg/ml) was injected SC into the
dorsal area of the mice. After 14–16 weeks the tumour weighed
0.2–0.4 g and was not grossly necrotic. Tumour tissues of some
random animals were sent for pathological tests and were diag-
nosed as fibrosarcoma.
Biodistribution in wild-type and fibrosarcoma-bearing
animal tissues
The distribution of the radiolabelled complex among tissues
was determined for normal rats immediately after imaging. The
total amount of radioactivity (35 ± 2 μCi) injected into each rat was
measured by counting the 1-ml syringe before and after injection
in a dose calibrator with fixed geometry.
The animals were sacrificed by CO2 asphyxiation at selected
times after injection (0.5, 1, 24, and 48), the tissues (blood, heart,
lung, brain, intestine, faeces, skin, stomach, kidneys, liver, muscle,
and bone) were weighed and rinsed with normal saline, and their
specific activities were determined with an HPGe detector equipped
with a sample holder device, as the percentage of injected dose
per gram of tissue.
Results and discussion
Although there are reports on the reaction of acetyl acetone and
thiosemicarbazides in the literature showing that the reaction is com-
plicated by the possible formation of pyrazoline forms [21], it has
fortunately been shown that these compounds, in the presence of
mild acidic conditions (pH = 4–6) and metallic ions, afford in the
metallic bis-thiosemicarbazonate complexes [22]. These studies are
mostly performed in presence of copper and nickel cations although
it is very possible that a similarity would be observed for Ga cations
as well. A major drawback in copper complexes has proven to be
the oxidation of the methylene backbone of the complex, while in 15
hours the oxidized species can be observed [17], leading to the
formation of copper cations. Although we did not have any proof
regarding the oxidation of the Ga complexes, the whole radiolabel-
ling procedure was performed under N2 atmosphere to avoid pos-
sible oxidation. According to our knowledge, there are no reports of
other Ga oxidation states in the literature.
Production
Gallium-67, as GaCl3, was prepared by 24 MeV proton bom-
bardment of the 68Zn target at Cyclone-30 on a regular basis. The
target was bombarded with a current intensity of 170 mA and
a charge of 1400 mAh. The chemical separation process was based
on a no-carrier-added method.
Radiochemical separation was performed by two-step ion ex-
change chromatography method with a yield higher than 95%.
Quality control of the product was performed in two steps. Radio-
nuclidic control showed the presence of 93 (40%), 184 (24%), 296
(22%), and 378 (7%) keV gamma energies, all originating from 67Ga,
and showed a radionuclidic purity higher than 99% (E.O.S.). The
concentrations of zinc (from target material) and copper (from tar-
get support) were determined using visible colorimetric assays
and were shown to be below the internationally accepted levels,
i.e. 1 ppm Zn [14] and 5 ppm for Cu [15].
Radiolabelling of [67Ga]AATS
Because of the engagement of several polar functional groups
in its structure, labelling of AATS with a gallium cation affects its
chromatographic properties, and the final complex is more lipo-
philic. Thus free gallium remains at the origin (Rf. 0.0), while the
radiolabelled complex migrates to a higher Rf (0.86) (Figure 2).
The lipophilic nature of the complex was a major reason in
HPLC distinct radio-analysis, and a reverse phase column was
preferable. Free Ga eluted at 1.99 minutes while the complex was
eluted at 18.57 minutes, demonstrating a radiochemical purity of
93 percent using optimized conditions without further purification
(Figure 3).
Optimization
At room temperature, no detectable complex was formed. The
best temperature was found to be 85–90oC. At this temperature,
when freshly prepared gallium-67 was used, all the radio-gallium
was inserted into the complex. While heating the reaction mixture
to over 100oC or for more than 1h, the radiochemical yield dropped.
The final radiolabelled complex in alcoholic media was diluted in
normal saline to a 5% solution.
The solution was stable at room temperature for up to 4 days
post-formulation, allowing performance of biological experiments.
Before experiments, the solution passed through a 0.22 mm filter
(Millipore).
Stability
The chemical stability of [67Ga]AATS was high enough to per-
form further studies. Incubation of [67Ga]AATS in freshly prepared
human serum for 2 days at 37°C showed no loss of 67Ga from the
complex. The radiochemical purity of the complex remained
at 95 ± 3% for 4 days under physiologic conditions.
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Biodistribution
One hour post-injection, the radioactivity was enhanced in the
kidneys (Figure 4). This pattern rapidly dropped after two hours.
The radioactivity of intestine as well as GI tract was high at two
hours, which could be due to the metabolism of the radiolabelled
complex in the liver. The pattern for sternum, skin, and brain re-
mained almost unchanged. The major excretion route for the tra-
cer is the urinary tract, as shown in Figure 4. A clear accumulation
occurred in the spleen and the reticuloendothelial system after 24
hours, possibly due to the biodistribution of free Ga3+.
The biodistribution data for radiolabelled compound in fibro-
sarcoma-bearing mice is presented in Figure 5. The tumour up-
take is not significant for at least one hour post-injection; however,
at two hours, major activity content (6–7%) accumulated in the tu-
mour mass. Nevertheless, after 48 hours the tumour uptake faded.
This is an interesting result since compared to the Ga3+ cation usu-
ally the tumour uptake increases after 24–48 hours due to various
suggested mechanisms such as transferrin receptors and/or acid-
ity of the tumour cells [23]
Conclusions
Total labelling and formulation of [67Ga]AATS took about
40 minutes, with a radiochemical purity higher than 93% (HPLC).
A significant specific activity (9.1 TBq/mmol or 246 Ci/mmol)
was formed via insertion of 67Ga cations. The radiolabelled com-
plex was stable in aqueous solutions for at least 4 days, and 2
days in the presence of human serum, and no significant
amount of other radioactive species were detected by ITLC 12
hours after labelling. Trace amounts of [67Ga]gallium cation
(ª 4%) were detected by ITLC, which showed that radiochem-
ical purity of the [67Ga]AATS was higher than 96%; in HPLC
studies a radiochemical purity of 93% was detected. The bio-
distribution of the tracer in wild-type rats demonstrated that
the major route of excretion is the urinary tract. The tracer af-
forded significant tumour uptake (7%) after 24 hours in fibro-
sarcoma-bearing mice. [67Ga]AATS can be a potential SPECT
radiotracer for malignancy imaging. Further investigations on
other tumour models and trapping mechanisms are required,
while production of 68Ga homologue can be of great interest
for PET studies.
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